SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-15-010809
Filing Date
2015-01-14
Accepted
2015-01-14 17:23:10
Documents
8
Period of Report
2015-02-27
Effectiveness Date
2015-01-14

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d829151ddef14a.htm DEF 14A 257849
2 GRAPHIC g829151g12c39.jpg GRAPHIC 9412
3 GRAPHIC g829151g23e48.jpg GRAPHIC 2694
4 GRAPHIC g829151g59k96.jpg GRAPHIC 3044
5 GRAPHIC g829151g61r59.jpg GRAPHIC 21395
6 GRAPHIC g829151g62e24.jpg GRAPHIC 3041
7 GRAPHIC g829151g81w06.jpg GRAPHIC 2806
8 GRAPHIC g829151g97z57.jpg GRAPHIC 7065
  Complete submission text file 0001193125-15-010809.txt   328177
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12465 | Film No.: 15527868
SIC: 2834 Pharmaceutical Preparations